Cited 0 times in
Phase 1 trial of vibostolimab plus pembrolizumab for PD-1/PD-L1 inhibitor-naive advanced gastric cancer: The KEYVIBE-001 trial
DC Field | Value | Language |
---|---|---|
dc.date.accessioned | 2023-06-02T01:05:41Z | - |
dc.date.available | 2023-06-02T01:05:41Z | - |
dc.date.issued | 2022-06 | - |
dc.identifier.issn | 0923-7534 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/194647 | - |
dc.description.statementOfResponsibility | restriction | - |
dc.language | English | - |
dc.publisher | Oxford University Press | - |
dc.relation.isPartOf | ANNALS OF ONCOLOGY | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.title | Phase 1 trial of vibostolimab plus pembrolizumab for PD-1/PD-L1 inhibitor-naive advanced gastric cancer: The KEYVIBE-001 trial | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학교실) | - |
dc.contributor.googleauthor | K. Shitara | - |
dc.contributor.googleauthor | T. Golan | - |
dc.contributor.googleauthor | K. Mileham | - |
dc.contributor.googleauthor | M. Voskoboynik | - |
dc.contributor.googleauthor | S. Rha | - |
dc.contributor.googleauthor | M. Gutierrez | - |
dc.contributor.googleauthor | R. Perets | - |
dc.contributor.googleauthor | S. Taylor | - |
dc.contributor.googleauthor | D. Chen | - |
dc.contributor.googleauthor | T. Keenan | - |
dc.contributor.googleauthor | M. Rajasagi | - |
dc.contributor.googleauthor | J. Healy | - |
dc.contributor.googleauthor | H. Shoji | - |
dc.identifier.doi | 10.1016/j.annonc.2022.04.081 | - |
dc.relation.journalcode | J00171 | - |
dc.identifier.eissn | 1569-8041 | - |
dc.identifier.url | https://www.sciencedirect.com/science/article/pii/S0923753422007712 | - |
dc.citation.volume | 33 | - |
dc.citation.number | Suppl 4 | - |
dc.citation.startPage | S240 | - |
dc.identifier.bibliographicCitation | ANNALS OF ONCOLOGY, Vol.33(Suppl 4) : S240, 2022-06 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.